Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops cPMP (cyclic Pyranopterin Monophosphate) (ALXN 1101) for molybdenum cofactor deficiency disease type A; and Samalizumab (ALXN6000), an immunomodulatory humanized monoclonal antibody. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products; and collaboration with Dicerna Pharmaceuticals, Inc. to discover and develop RNAi therapies for complement-mediated diseases. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone475-230-2596
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.55 billion
Profitability
Miscellaneous
Employees2,525
OptionableOptionable
Alexion Pharmaceuticals (NASDAQ:ALXN) Frequently Asked Questions
What is Alexion Pharmaceuticals' stock symbol?
Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."
How will Alexion Pharmaceuticals' stock buyback program work?
Alexion Pharmaceuticals announced that its board has authorized a stock buyback plan on Sunday, April 9th 2017, which permits the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 3.4% of its stock through open market purchases. Stock buyback plans are generally an indication that the company's board believes its shares are undervalued.
How were Alexion Pharmaceuticals' earnings last quarter?
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) posted its quarterly earnings data on Wednesday, October, 24th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts' consensus estimates of $1.74 by $0.28. The biopharmaceutical company had revenue of $1.03 billion for the quarter, compared to analysts' expectations of $1.02 billion. Alexion Pharmaceuticals had a net margin of 3.90% and a return on equity of 16.60%. Alexion Pharmaceuticals's quarterly revenue was up 19.5% compared to the same quarter last year. During the same period last year, the company earned $1.44 EPS. View Alexion Pharmaceuticals' Earnings History.
When is Alexion Pharmaceuticals' next earnings date?
How can I listen to Alexion Pharmaceuticals' earnings call?
Alexion Pharmaceuticals will be holding an earnings conference call on Monday, February 4th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8667623111.
What guidance has Alexion Pharmaceuticals issued on next quarter's earnings?
Alexion Pharmaceuticals issued an update on its FY18 earnings guidance on Wednesday, October, 24th. The company provided EPS guidance of $7.45-7.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.24. The company issued revenue guidance of $4.02-4.05 billion, compared to the consensus revenue estimate of $4.04 billion.Alexion Pharmaceuticals also updated its FY 2018 guidance to $7.45-7.60 EPS.
What price target have analysts set for ALXN?
17 equities research analysts have issued 1-year price targets for Alexion Pharmaceuticals' shares. Their predictions range from $123.00 to $190.00. On average, they anticipate Alexion Pharmaceuticals' stock price to reach $165.1875 in the next year. This suggests a possible upside of 44.1% from the stock's current price. View Analyst Price Targets for Alexion Pharmaceuticals.
What is the consensus analysts' recommendation for Alexion Pharmaceuticals?
17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. There are currently 2 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alexion Pharmaceuticals.
Has Alexion Pharmaceuticals been receiving favorable news coverage?
News headlines about ALXN stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Alexion Pharmaceuticals earned a news impact score of 0.7 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term.
Who are some of Alexion Pharmaceuticals' key competitors?
Some companies that are related to Alexion Pharmaceuticals include GlaxoSmithKline (GSK), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Shire (SHPG), Allergan (AGN), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Zoetis (ZTS), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA) and BioMarin Pharmaceutical (BMRN).
Who are Alexion Pharmaceuticals' key executives?
Alexion Pharmaceuticals' management team includes the folowing people:
- Dr. Ludwig N. Hantson, CEO & Director (Age 56)
- Mr. Paul J. Clancy, Exec. VP & CFO (Age 57)
- Mr. Brian Goff, Exec. VP & Chief Commercial Officer (Age 50)
- Mr. Daniel A. Bazarko CPA, Chief Accounting Officer & Sr. VP
- Ms. Indrani M. Lall Franchini, Exec. VP & Chief Compliance Officer (Age 47)
Who are Alexion Pharmaceuticals' major shareholders?
Alexion Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Factory Mutual Insurance Co. (0.31%), Peregrine Capital Management LLC (0.07%), Gateway Investment Advisers LLC (0.06%), Vigilant Capital Management LLC (0.05%), Nisa Investment Advisors LLC (0.03%) and Gulf International Bank UK Ltd (0.02%). Company insiders that own Alexion Pharmaceuticals stock include Ann M Veneman, Bros Advisors Lp Baker, Carsten Thiel, Christopher J Coughlin, Clare Carmichael, Edward Miller, Heidi L Wagner, Indrani Lall Franchini, John B Moriarty, John J Orloff, Julie O'neill, Leonard Bell, Ludwig Hantson and Paul J Clancy. View Institutional Ownership Trends for Alexion Pharmaceuticals.
Which major investors are selling Alexion Pharmaceuticals stock?
ALXN stock was sold by a variety of institutional investors in the last quarter, including Gulf International Bank UK Ltd, Boston Advisors LLC, Tealwood Asset Management Inc., Louisiana State Employees Retirement System, DNB Asset Management AS, Vigilant Capital Management LLC and Edge Wealth Management LLC. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Heidi L Wagner, Indrani Lall Franchini, John B Moriarty, John J Orloff, Julie O'neill, Ludwig Hantson and Paul J Clancy. View Insider Buying and Selling for Alexion Pharmaceuticals.
Which major investors are buying Alexion Pharmaceuticals stock?
ALXN stock was bought by a variety of institutional investors in the last quarter, including Centre Asset Management LLC, Factory Mutual Insurance Co., Virtu Financial LLC, Peregrine Capital Management LLC, QUANTRES ASSET MANAGEMENT Ltd, Fox Run Management L.L.C., Meeder Asset Management Inc. and State of Alaska Department of Revenue. Company insiders that have bought Alexion Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Christopher J Coughlin and Ludwig Hantson. View Insider Buying and Selling for Alexion Pharmaceuticals.
How do I buy shares of Alexion Pharmaceuticals?
Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alexion Pharmaceuticals' stock price today?
One share of ALXN stock can currently be purchased for approximately $114.62.
How big of a company is Alexion Pharmaceuticals?
Alexion Pharmaceuticals has a market capitalization of $24.92 billion and generates $3.55 billion in revenue each year. The biopharmaceutical company earns $443.30 million in net income (profit) each year or $5.16 on an earnings per share basis. Alexion Pharmaceuticals employs 2,525 workers across the globe.
What is Alexion Pharmaceuticals' official website?
How can I contact Alexion Pharmaceuticals?
Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]
MarketBeat Community Rating for Alexion Pharmaceuticals (NASDAQ ALXN)
MarketBeat's community ratings are surveys of what our community members think about Alexion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALXN will underperform the S&P 500 over the long term. You may vote once every thirty days.
